Overview

Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.

Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the efficacy and safety of SAR97276A in severe malaria in pediatric patients. Before treating pediatric patients with severe malaria, the efficacy and safety of SAR97276A will be first tested in adult patients, then in pediatric patients, with uncomplicated malaria. The safety and the concentration of SAR97276A in blood and plasma will be assessed in adult and pediatric patients.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi